Cargando…

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

The objective of this study was to determine copy number variant (CNV) and promoter genetic variants in glutathione S-transferase Mu class 1 (GSTM1) and the risk of recurrence (REC)/second primary tumor (SPT) in patients with previously diagnosed early stage head and neck cancer. Among 441 subjects,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuemei, Huang, Maosheng, Wu, Xifeng, Kadlubar, Susan, Lin, Jie, Yu, Xinfeng, Fan, Chunyang, Ning, Baitang, Kadlubar, Fred F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596140/
https://www.ncbi.nlm.nih.gov/pubmed/23526580
http://dx.doi.org/10.2147/PGPM.S35949
_version_ 1782262469948866560
author Zhang, Xuemei
Huang, Maosheng
Wu, Xifeng
Kadlubar, Susan
Lin, Jie
Yu, Xinfeng
Fan, Chunyang
Ning, Baitang
Kadlubar, Fred F
author_facet Zhang, Xuemei
Huang, Maosheng
Wu, Xifeng
Kadlubar, Susan
Lin, Jie
Yu, Xinfeng
Fan, Chunyang
Ning, Baitang
Kadlubar, Fred F
author_sort Zhang, Xuemei
collection PubMed
description The objective of this study was to determine copy number variant (CNV) and promoter genetic variants in glutathione S-transferase Mu class 1 (GSTM1) and the risk of recurrence (REC)/second primary tumor (SPT) in patients with previously diagnosed early stage head and neck cancer. Among 441 subjects, 133 experienced REC and/or an SPT, while 308 had single primary disease. TaqMan real-time polymerase chain reaction was used to measure the exact copy number of GSTM1 and direct sequencing was used to determine genetic variants in the GSTM1 promoter region. Multivariate Cox regression analysis was performed to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) associated with copy number and genetic variants. REC/SPT-free survival times were compared by constructing Kaplan–Meier curves and differences between curves were tested by logrank test. Results showed a significantly decreased REC/SPT (HR = 0.57; 95% CI = 0.35–0.95) and longer REC/SPT-free survival in subjects with at least two copies of GSTM1 compared with the GSTM1 homozygous deletion, but not in those with one copy of GSTM1. The −498G, −426G, and −339T alleles were significantly associated with REC/SPT, with HRs of 0.11 (0.02–0.85), 0.28 (0.11–0.74) and 2.02 (1.07–3.82), respectively. Kaplan–Meier survival analysis showed that the −498G, −426G, and −339C alleles were also significantly associated with increased REC/SPT-free survival. Further haplotype analysis showed the haplotype P(−498G-−426G-−339C) carriers had decreased REC/SPT with a HR of 0.09 (95% CI 0.01–0.71) and increased REC/SPT-free survival compared with those with haplotype P(−498C-−426A-−339T). The P(−498C-−426A-−339T)-containing reporter construct had significantly increased luciferase expression. These results suggest that the GSTM1 CNV and promoter haplotype are better predictors of REC/SPTs of head and neck cancer than just measuring the presence/absence of GSTM1.
format Online
Article
Text
id pubmed-3596140
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35961402013-03-22 GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer Zhang, Xuemei Huang, Maosheng Wu, Xifeng Kadlubar, Susan Lin, Jie Yu, Xinfeng Fan, Chunyang Ning, Baitang Kadlubar, Fred F Pharmgenomics Pers Med Original Research The objective of this study was to determine copy number variant (CNV) and promoter genetic variants in glutathione S-transferase Mu class 1 (GSTM1) and the risk of recurrence (REC)/second primary tumor (SPT) in patients with previously diagnosed early stage head and neck cancer. Among 441 subjects, 133 experienced REC and/or an SPT, while 308 had single primary disease. TaqMan real-time polymerase chain reaction was used to measure the exact copy number of GSTM1 and direct sequencing was used to determine genetic variants in the GSTM1 promoter region. Multivariate Cox regression analysis was performed to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) associated with copy number and genetic variants. REC/SPT-free survival times were compared by constructing Kaplan–Meier curves and differences between curves were tested by logrank test. Results showed a significantly decreased REC/SPT (HR = 0.57; 95% CI = 0.35–0.95) and longer REC/SPT-free survival in subjects with at least two copies of GSTM1 compared with the GSTM1 homozygous deletion, but not in those with one copy of GSTM1. The −498G, −426G, and −339T alleles were significantly associated with REC/SPT, with HRs of 0.11 (0.02–0.85), 0.28 (0.11–0.74) and 2.02 (1.07–3.82), respectively. Kaplan–Meier survival analysis showed that the −498G, −426G, and −339C alleles were also significantly associated with increased REC/SPT-free survival. Further haplotype analysis showed the haplotype P(−498G-−426G-−339C) carriers had decreased REC/SPT with a HR of 0.09 (95% CI 0.01–0.71) and increased REC/SPT-free survival compared with those with haplotype P(−498C-−426A-−339T). The P(−498C-−426A-−339T)-containing reporter construct had significantly increased luciferase expression. These results suggest that the GSTM1 CNV and promoter haplotype are better predictors of REC/SPTs of head and neck cancer than just measuring the presence/absence of GSTM1. Dove Medical Press 2013-03-01 /pmc/articles/PMC3596140/ /pubmed/23526580 http://dx.doi.org/10.2147/PGPM.S35949 Text en © 2013 Zhang et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Zhang, Xuemei
Huang, Maosheng
Wu, Xifeng
Kadlubar, Susan
Lin, Jie
Yu, Xinfeng
Fan, Chunyang
Ning, Baitang
Kadlubar, Fred F
GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
title GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
title_full GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
title_fullStr GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
title_full_unstemmed GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
title_short GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
title_sort gstm1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596140/
https://www.ncbi.nlm.nih.gov/pubmed/23526580
http://dx.doi.org/10.2147/PGPM.S35949
work_keys_str_mv AT zhangxuemei gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT huangmaosheng gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT wuxifeng gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT kadlubarsusan gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT linjie gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT yuxinfeng gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT fanchunyang gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT ningbaitang gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer
AT kadlubarfredf gstm1copynumberandpromoterhaplotypeaspredictorsforriskofrecurrenceandorsecondprimarytumorinpatientswithheadandneckcancer